179 related articles for article (PubMed ID: 30864579)
1. Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease.
Meden A; Knez D; Jukič M; Brazzolotto X; Gršič M; Pišlar A; Zahirović A; Kos J; Nachon F; Svete J; Gobec S; Grošelj U
Chem Commun (Camb); 2019 Mar; 55(26):3765-3768. PubMed ID: 30864579
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Dighe SN; Deora GS; De la Mora E; Nachon F; Chan S; Parat MO; Brazzolotto X; Ross BP
J Med Chem; 2016 Aug; 59(16):7683-9. PubMed ID: 27405689
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors.
Meden A; Knez D; Malikowska-Racia N; Brazzolotto X; Nachon F; Svete J; Sałat K; Grošelj U; Gobec S
Eur J Med Chem; 2020 Dec; 208():112766. PubMed ID: 32919297
[TBL] [Abstract][Full Text] [Related]
4. Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.
Chalupova K; Korabecny J; Bartolini M; Monti B; Lamba D; Caliandro R; Pesaresi A; Brazzolotto X; Gastellier AJ; Nachon F; Pejchal J; Jarosova M; Hepnarova V; Jun D; Hrabinova M; Dolezal R; Zdarova Karasova J; Mzik M; Kristofikova Z; Misik J; Muckova L; Jost P; Soukup O; Benkova M; Setnicka V; Habartova L; Chvojkova M; Kleteckova L; Vales K; Mezeiova E; Uliassi E; Valis M; Nepovimova E; Bolognesi ML; Kuca K
Eur J Med Chem; 2019 Apr; 168():491-514. PubMed ID: 30851693
[TBL] [Abstract][Full Text] [Related]
5. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
6. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Boltneva NP; Serebryakova OG; Rudakova EV; Ustyugov AA; Bachurin SO; Shchepochkin AV; Chupakhin ON; Charushin VN; Richardson RJ
Bioorg Med Chem; 2017 Nov; 25(21):5981-5994. PubMed ID: 28986116
[TBL] [Abstract][Full Text] [Related]
7. Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.
Khan I; Ibrar A; Zaib S; Ahmad S; Furtmann N; Hameed S; Simpson J; Bajorath J; Iqbal J
Bioorg Med Chem; 2014 Nov; 22(21):6163-73. PubMed ID: 25257911
[TBL] [Abstract][Full Text] [Related]
8. Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
van Greunen DG; Johan van der Westhuizen C; Cordier W; Nell M; Stander A; Steenkamp V; Panayides JL; Riley DL
Eur J Med Chem; 2019 Oct; 179():680-693. PubMed ID: 31280020
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors.
Pejchal V; Štěpánková Š; Pejchalová M; Královec K; Havelek R; Růžičková Z; Ajani H; Lo R; Lepšík M
Bioorg Med Chem; 2016 Apr; 24(7):1560-72. PubMed ID: 26947959
[TBL] [Abstract][Full Text] [Related]
11. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Košak U; Knez D; Coquelle N; Brus B; Pišlar A; Nachon F; Brazzolotto X; Kos J; Colletier JP; Gobec S
Bioorg Med Chem; 2017 Jan; 25(2):633-645. PubMed ID: 27908752
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.
Sawatzky E; Wehle S; Kling B; Wendrich J; Bringmann G; Sotriffer CA; Heilmann J; Decker M
J Med Chem; 2016 Mar; 59(5):2067-82. PubMed ID: 26886849
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening.
Atatreh N; Al Rawashdah S; Al Neyadi SS; Abuhamdah SM; Ghattas MA
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1373-1379. PubMed ID: 31347933
[TBL] [Abstract][Full Text] [Related]
14. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Pajk S; Knez D; Košak U; Zorović M; Brazzolotto X; Coquelle N; Nachon F; Colletier JP; Živin M; Stojan J; Gobec S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):498-505. PubMed ID: 31914836
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
16. An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.
Rehman TU; Khan IU; Ashraf M; Tarazi H; Riaz S; Yar M
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220522
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.
Xi M; Feng C; Du K; Lv W; Du C; Shen R; Sun H
Bioorg Med Chem Lett; 2022 Apr; 61():128602. PubMed ID: 35124202
[TBL] [Abstract][Full Text] [Related]
18. New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease.
Boulebd H; Ismaili L; Martin H; Bonet A; Chioua M; Marco Contelles J; Belfaitah A
Future Med Chem; 2017 May; 9(8):723-729. PubMed ID: 28485637
[TBL] [Abstract][Full Text] [Related]
19. Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles.
Ozadali-Sari K; Tüylü Küçükkılınç T; Ayazgok B; Balkan A; Unsal-Tan O
Bioorg Chem; 2017 Jun; 72():208-214. PubMed ID: 28478328
[TBL] [Abstract][Full Text] [Related]
20. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
